Bioage Labs, Stock Today
| BIOA Stock | 19.29 0.41 2.08% |
Performance3 of 100
| Odds Of DistressOver 75
|
BioAge Labs, is trading at 19.29 as of the 29th of November 2024, a 2.08 percent decrease since the beginning of the trading day. The stock's open price was 19.7. BioAge Labs, has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for BioAge Labs, are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of October 2024 and ending today, the 29th of November 2024. Click here to learn more.
IPO Date 26th of September 2024 | Category Healthcare |
BioAmber Inc., an industrial biotechnology company, produces and sells renewable chemicals worldwide. BioAmber Inc. was founded in 2008 is headquartered in Montreal, Canada. BioAmber operates under Chemicals classification in USA and traded on OTC Market. It employs 85 people. The company has 34.17 M outstanding shares of which 2.37 M shares are currently shorted by private and institutional investors with about 0.0 trading days to cover. More on BioAge Labs,
Moving against BioAge Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
BioAge Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO, CoFounder | Kristen Fortney | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | BioAmber Inc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceutical Products, Drug Manufacturers - Specialty & Generic, Healthcare, null, null, Chemicals - Major Diversified, Basic Materials (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BioAge Labs, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BioAge Labs,'s financial leverage. It provides some insight into what part of BioAge Labs,'s total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BioAge Labs, (BIOA) is traded on NASDAQ Exchange in USA. It is located in 1445A South 50th Street, Richmond, CA, United States, 94804 and employs 56 people. BioAge Labs, is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 674.12 M. BioAge Labs, conducts business under null sector and is part of null industry. The entity has 34.17 M outstanding shares of which 2.37 M shares are currently shorted by private and institutional investors with about 0.0 trading days to cover.
BioAge Labs, currently holds about 4.63 M in cash with (37.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04.
Check BioAge Labs, Probability Of Bankruptcy
Ownership AllocationBioAge Labs, holds a total of 34.17 Million outstanding shares. 30% of BioAge Labs, outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check BioAge Ownership Details
BioAge Labs, Historical Income Statement
BioAge Stock Against Markets
BioAge Labs, Corporate Management
| MD MBA | Chief Officer | Profile | |
| Justin Rebo | Senior Biology | Profile | |
| Rusty Montgomery | Senior Research | Profile | |
| Paul MD | Chief Research | Profile | |
| Peng MBA | Chief Aging | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioAge Labs,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade BioAge Stock refer to our How to Trade BioAge Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAge Labs,. If investors know BioAge will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAge Labs, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.40) |
The market value of BioAge Labs, is measured differently than its book value, which is the value of BioAge that is recorded on the company's balance sheet. Investors also form their own opinion of BioAge Labs,'s value that differs from its market value or its book value, called intrinsic value, which is BioAge Labs,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAge Labs,'s market value can be influenced by many factors that don't directly affect BioAge Labs,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAge Labs,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAge Labs, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAge Labs,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.